ArticleScientific reports2026
Development and evaluation of recombinant dense granule 14 for serological diagnosis of Toxoplasma gondii infection in domestic cats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of recombinant TgGRA14 as a diagnostic antigen for detection of Toxoplasma gondii antibodies in cattle.BMC veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Toxoplasma gondii is a widespread zoonotic protozoan parasite, with domestic cats as definitive hosts. To improve serodiagnosis surveillance and control, this study aimed to develop and evaluate an indirect enzyme-linked immunosorbent assay (iELISA) using recombinant TgGRA14 protein for the serological detection of T. gondii in domestic cats. The TgGRA14 gene (nucleotides 114–858 encoding amino acids 38–286) was synthesized and cloned into the pET-28a vector containing an N-terminal FLAG tag. The recombinant plasmid was transformed into E. coli BL21, and protein expression was purified via anti-FLAG affinity chromatography. Protein integrity, antigenicity and identity was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), blotting, while mass spectrometry verified protein identity. The purified TgGRA14 protein was used as a coating antigen in iELISA, which was applied to 149 feline serum samples and compared with results from the indirect fluorescent antibody test (IFAT). The recombinant TgGRA14 protein (approximately 29 kDa) was successfully expressed and purified, with confirmed antigenicity and 99.6–100% identity by mass spectrometry. The iELISA detected 38.3% seroprevalence in feline samples, compared to 32.9% by IFAT, and showed high diagnostic performance with 95.9% sensitivity, 90.0% specificity, and a kappa value of 0.824. These results indicate that the iELISA based on recombinant TgGRA14 is a highly sensitive and specific diagnostic tool for detecting T. gondii infection in domestic cats, which has strong potential for application in epidemiological surveillance and serological screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.